Identification of immune signatures associated with both SARS-CoV-2 infection and lung transplantation.

Hoffmann, Andrew D; Almubarak, Hannah Faisal; Iyer, Radhika; Weinberg, Sam E; Squires, Joshua R; Mao, Chengsheng; Wei, Juncheng; Chaudhuri, Shuvam et al. · Cell Rep Med · 2025

case_series · Level IV

Where this comes from

Abstract

Lung transplantation (lung-tx) offers the last life-saving option for patients with COVID-19-associated lung injury (CALI). We show that the RBD-specific antibodies are dramatically reduced in these CALI lung-tx patients despite a comparable frequency of CD19<sup>+</sup> B cells in circulating blood between CALI lung-tx patients and sero-negative controls. In contrast, non-transplant COVID-19 groups maintain a high level of RBD-specific antibodies. Single-cell RNA sequencing of white blood cells (WBCs) reveals three populations expanded in CALI lung-tx patients, including "lung-tx CD14<sup>+</sup>FCGR3B(CD16b)<sup>+</sup> neutrophils," "lung-tx CD8<sup>+</sup> T cells," and "KLF2<sup>+</sup> CD4<sup>+</sup> T cells," alongside reduced conventional T and B lymphocytes. Elevated expression of interferon (IFN)-responsive genes as part of COVID-19 molecular signatures is sustained in some clusters of monocytes, Tregs, and B cells in all COVID-19 groups. Multiplex analysis of cytokines and chemokines detects a statistically significant increase in interleukin (IL)-6, IL-8, MCP-1, and MIP-1α in circulating blood, specifically in CALI lung-tx patients.

Medical subject headings